Hammersmith gets local connection rule
London local authority restricts social housing.
Yet another London borough authority has moved to stem the flow of people applying for social housing, with only those with a five-year connection to the local area permitted access to subsidised homes.
According to Hammersmith and Fulham council, new sanctions will be put into place in order to prioritise "local homes for local people", with a residency test being introduced as part of the application process.
The district follows an example set by Kensington and Chelsea, which last month stated that only vulnerable parties from local areas will be offered social tenancies and terminated lifetime contracts.
Prime minister David Cameron last week advocated the changes and told local authorities all over the country that they should be implementing the same measures in an attempt to control social housing waiting lists, which have been spinning out of control.
Councillor Andrew Johnson, the council's cabinet member for housing, said: “It cannot be fair for decent, honest people to sit on a council housing register for years and years and then see their housing dreams turn to dust when a new migrant, or someone from elsewhere in the country overtakes them in the queue."
The council stated that one person had been on the list for social housing for 36 years, while last year just 470 new lettings were made. It is hoped that adjustments to housing policy will avoid situations like these.
"Hammersmith and Fulham Council is … changing the rules so that local people with a five year connection to the borough come first," Mr Johnson concluded.
The local authority is currently constructing homes to add to its extensive portfolio of social housing, having started up its own company last year to deal with an influx of applications for affordable housing.
It hopes to have completed 500 low-cost units within the next ten years.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...